Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
$33.14
-2.6%
$42.80
$32.96
$67.88
$2.84B1.771.56 million shs2.18 million shs
Invitae Co. stock logo
NVTA
Invitae
$0.00
$0.00
$0.02
$0.02
$80K1.5923.72 million shs75 shs
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
$1.13
-4.2%
$1.45
$1.08
$3.70
$336.57M1.8610.10 million shs5.78 million shs
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
-2.62%-18.95%-24.54%-15.80%-51.39%
Invitae Co. stock logo
NVTA
Invitae
0.00%0.00%0.00%0.00%-97.27%
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
-4.24%-13.74%-22.07%-38.25%-69.04%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
3.2485 of 5 stars
4.22.00.00.02.13.30.6
Invitae Co. stock logo
NVTA
Invitae
1.1276 of 5 stars
0.00.00.04.60.61.71.3
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
2.4993 of 5 stars
3.33.00.00.02.50.81.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
2.48
Hold$73.11120.60% Upside
Invitae Co. stock logo
NVTA
Invitae
0.00
N/AN/AN/A
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
2.54
Moderate Buy$2.46117.55% Upside

Current Analyst Ratings Breakdown

Latest CRSP, PACB, and NVTA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/25/2025
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Outperform ➝ Sector Outperform$6.00 ➝ $2.00
2/20/2025
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$2.50 ➝ $2.00
2/19/2025
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral
2/18/2025
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$89.00 ➝ $82.00
2/18/2025
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$1.75 ➝ $1.50
2/14/2025
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetUnderweight ➝ Underweight$30.00 ➝ $32.00
2/14/2025
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeIn-Line ➝ Outperform$60.00 ➝ $99.00
2/14/2025
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$2.50 ➝ $2.50
2/13/2025
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$66.00 ➝ $57.00
2/13/2025
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$53.00 ➝ $49.00
2/13/2025
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$86.00 ➝ $86.00
(Data available from 4/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
$35M81.22N/AN/A$22.52 per share1.47
Invitae Co. stock logo
NVTA
Invitae
$481.58M0.00N/AN/A$0.42 per share0.00
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
$154.01M2.19N/AN/A$2.62 per share0.43
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
-$366.25M-$4.37N/AN/AN/A-981.54%-18.46%-15.79%5/6/2025 (Estimated)
Invitae Co. stock logo
NVTA
Invitae
-$3.11B-$5.38N/AN/AN/A-299.14%-6,100.71%-19.68%N/A
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
-$308.65M-$1.64N/AN/AN/A-200.40%-42.89%-14.77%5/8/2025 (Estimated)

Latest CRSP, PACB, and NVTA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
2/13/2025Q4 2024
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
-$0.20-$0.20N/A-$0.49$39.20 million$39.22 million
2/11/2025Q4 2024
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
-$1.15-$0.44+$0.71-$0.44N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
N/AN/AN/AN/AN/A
Invitae Co. stock logo
NVTA
Invitae
N/AN/AN/AN/AN/A
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
N/A
22.07
22.07
Invitae Co. stock logo
NVTA
Invitae
N/A
2.39
2.25
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
1.97
9.74
8.64

Institutional Ownership

CompanyInstitutional Ownership
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
69.20%
Invitae Co. stock logo
NVTA
Invitae
61.28%
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
N/A

Insider Ownership

CompanyInsider Ownership
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
4.10%
Invitae Co. stock logo
NVTA
Invitae
0.74%
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
2.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
47385.77 million82.26 millionOptionable
Invitae Co. stock logo
NVTA
Invitae
1,700267.01 million284.37 millionOptionable
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
730297.85 million267.29 millionOptionable

Recent News About These Companies

Cathie Wood’s ARK Investment bought 899K shares of PacBio today
Jim Gibson to join PacBio as Chief Financial Officer
Cathie Wood’s ARK Investment bought 415K shares of PacBio today

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRISPR Therapeutics stock logo

CRISPR Therapeutics NASDAQ:CRSP

$33.14 -0.89 (-2.62%)
Closing price 04/1/2025 04:00 PM Eastern
Extended Trading
$33.24 +0.10 (+0.32%)
As of 04:46 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Invitae stock logo

Invitae NYSE:NVTA

Invitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.

Pacific Biosciences of California stock logo

Pacific Biosciences of California NASDAQ:PACB

$1.13 -0.05 (-4.24%)
Closing price 04/1/2025 04:00 PM Eastern
Extended Trading
$1.15 +0.02 (+1.77%)
As of 04:31 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.